Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

faldaprevir

- PMLiVE

US charity calls for release of diabetes drug data

American Diabetes Association demands review of incretin-based medicines linked to pancreatic cancer

- PMLiVE

EMA seeks comment on final biosimilar guidance

Outlines thinking on non-clinical and clinical development requirements

- PMLiVE

Alcon wins initial NICE backing for Jetrea in rare eye condition

Would be first alternative to surgery available to vitreomacular traction patients in England and Wales

- PMLiVE

Boehringer says faldaprevir does well in Asian hepatitis C patients

Trial success in patients from Korea, Japan and Taiwan

- PMLiVE

Boehringer invests €35m in research centre in China

Teams up with Shanghai firm to build biopharma facility

- PMLiVE

ASCO: Boehringer’s nintedanib boosts survival in lung cancer subset

Trial date demonstrates benefit in NSCLC patients with adenocarcinomas

- PMLiVE

EMA backs Pomalidomide Celgene in multiple myeloma

Further positive CHMP opinions for new medicines form Aegerion, Teva and more

- PMLiVE

GSK/ Valeant’s Trobalt set for EU restrictions

Eye concerns prompt CHMP to recommend last-line use for the epilepsy drug

- PMLiVE

Novartis wins third NICE recommendation for Lucentis

Gains final backing to treat NHS patients with macular oedema

- PMLiVE

France ignores EMA and suspends Bayer’s Diane 35

National Agency for the Safety of Drugs and Health Products contradicts PRAC verdict

- PMLiVE

Boehringer’s Wolfram Carius to step down

He will be replaced by Wolfgang Baiker on the board of managing directors

Bayer symbol

EMA says Bayer’s Diane 35 should remain on European market

Agency investigation concludes acne treatment's benefits outweigh its risks

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links